Navigation Links
Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
Date:7/10/2012

MENLO PARK, Calif., July 10, 2012 /PRNewswire/ -- The Department of Defense (DoD) has awarded SRI International a one-year grant to develop a novel therapy for multiple sclerosis (MS), an autoimmune nervous system disease that affects about 400,000 people in the United States and more than two million people worldwide. There is currently no cure for this disorder, which can impair vision and movement.

The grant, funded through DoD's Congressionally Directed Medical Research Programs, will support the development of an oral drug that targets miR-326, a molecule recently found to stimulate the production of immune system mediators known as T-helper 17 (Th17) cells. Patients with MS have high levels of miR-326, and Th17 is thought to play a critical role in causing MS and other autoimmune diseases. The new therapy will inhibit miR-326 and block the production of Th17 cells.

The novel, orally administered drug will be more convenient for patients than currently available treatments. MS treatments today often require frequent hospital visits for injections or intravenous infusions. The new drug could also help patients who do not respond to existing medications, or who experience significant side effects as a result of taking them.

"New and more convenient and effective therapeutics for multiple sclerosis are greatly needed," said Jennifer Lam, Ph.D., a research scientist in SRI's Biosciences Division who is spearheading the project. "Our research is directed toward the development of a novel oral therapeutic as well as a deeper understanding of the mechanisms that contribute to MS."

The project described was supported by Award Numbers W81XWH-11-1-0736 from the U.S. Army Medical Research Acquisition Activity. The content of the information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred

About SRI's Biosciences Division
SRI's Biosciences Division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from Idea to IND®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to society—touching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more.


'/>"/>
SOURCE SRI International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
2. Researchers Evaluate Computer-based Treatment for People with Schizophrenia
3. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
4. Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices
5. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
6. Wound Management Products Market Reaches $15.2 Billion by 2016, Driven by Rising Demand for Bandages and Dressings in Developing World
7. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
8. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
9. Multiple Sclerosis Association of Americas MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
10. Aushon to Launch New Multiplex Immunoassay Platform
11. Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 10, 2017  BDI Group subsidiary Pathway Purchasing ... services organization serving specialty pharmacies, home infusion companies ... four significant, value-added member programs designed to help ... reimbursement and improve access and affordability for patients ... Pathway has ...
(Date:7/6/2017)... 6, 2017 ThriveRx, the nutrition division of Diplomat Specialty Infusion ... thrive on nutrition support. To celebrate its anniversary, ThriveRx recently ... a fresh new look with improved organization to create the best user ... ... "We,ve made several ...
(Date:7/5/2017)... company of over 2,000 employees and a leader in environmental and life science ... their position as the top American owned and operated environmental testing firm in ... ... ... , enhances Pace Analytical,s capability as an innovative full service provider in ...
Breaking Medicine Technology:
(Date:7/23/2017)... ... ... “Squiggy’s Outdoor Adventure”: a turtle’s backyard adventure that teaches the importance of ... Christian, a wife and mother to three amazing, and supportive, children. Paula lives ... God. She loves to tell stories to her children, play board games, bake, ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior ... the opportunity to return to sports and jobs that require heavy physical work, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 ...
(Date:7/21/2017)... Augusta, GA (PRWEB) , ... July 21, 2017 , ... ... is teaming up with the Epilepsy Foundation in a community wide charity event with ... region. , Delaney Sunde, a young local woman who lives with epilepsy, recently launched ...
(Date:7/21/2017)... ... , ... Fresh Wave® IAQ today announced the launch of its innovative ... at the APPA 2017 Annual Conference and Exhibition in Booth #414. , ... the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid ...
(Date:7/21/2017)... ... ... Margarian Law Firm has filed a class action lawsuit against Dr. Pepper ... Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In Gegham Margaryan ... claims on its bottle that it is made from real ginger. , When consumers ...
Breaking Medicine News(10 mins):